Sorafenib-associated psoriasiform skin changes

Cutis

Volumn 85, Issue 6, 2010, Pages 301-302

  Laquer, Vivian ^a   Saedi, Nazanin ^a   Dann, Frank ^a   Kelly, Kristen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; SORAFENIB;

CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; HAND; HUMAN; LETTER; MALE; MIDDLE AGED; PATHOLOGY; PSORIASIS;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DRUG ERUPTIONS; HAND; HUMANS; MALE; MIDDLE AGED; PSORIASIS; PYRIDINES;

EID: 77955779245     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008;58:545-570.
2. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512.
3. Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144:886-892.
4. Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60:299-305.